Last-Resort access to dupilumab for patients with severe inflammation
NCT ID NCT04776694
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This program provides compassionate use of dupilumab (Dupixent) for patients with severe type 2 inflammatory disorders who have no other treatment options. It aims to offer access to this drug outside of a clinical trial. The program is already approved for marketing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dupilumab (Dupixent)
- What this could lead to
- If successful, this could offer a treatment option for patients with severe type 2 inflammatory disorders who have exhausted other therapies.
- What could go wrong
- This is a compassionate use program, not a controlled trial, so results may not be generalizable. Dupilumab can cause side effects like injection site reactions and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 INFLAMMATORY DISORDERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.